Emil D. Kakkis
President & CEO at Ultragenyx Pharmaceutical Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Ultragenyx Pharmaceutical Inc., 3 years.
Ultragenyx Pharmaceutical Inc.
Director · President & CEO
Chief executive roles
Ultragenyx Pharmaceutical Inc.
· President & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 16, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +76,745 | — | — |
| Mar 2, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −54,404 | $22.80 | $1,240,411 |
| Mar 1, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +71,177 | — | — |
| Mar 3, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −73,434 | $42.10 | $3,091,571 |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +43,268 | — | — |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +107,292 | — | — |
| Feb 28, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −25,000 | $42.48 | $1,062,000 |
| Dec 30, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −11,727 | $42.23 | $495,231 |
| Dec 10, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −8,273 | $50.00 | $413,650 |
| Dec 9, 2024 | Ultragenyx Pharmaceutical Inc. | Gift | −20,000 | — | — |
| Sep 3, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −20,000 | $55.85 | $1,117,000 |
| Aug 6, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −20,000 | $50.17 | $1,003,400 |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +38,428 | — | — |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Shares withheld for tax | −17,417 | $53.69 | $935,119 |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +3,132 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.